Matches in SemOpenAlex for { <https://semopenalex.org/work/W2527388725> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2527388725 endingPage "7569" @default.
- W2527388725 startingPage "7569" @default.
- W2527388725 abstract "7569 Background: The combination of Interferon α-2b (INF) and intravenous Interleukin-2 (IL-2) with chemotherapy (CT) has produced encouraging results in metastatic melanoma, as shown in phase II and III trials, but toxicity remains of concern. We report on our experience with a chemo-immunotherapy regimen with subcutaneous administration of IL-2. Patients and methods: 28 patients (pts) with advanced melanoma, median age 47.5 years (range 29–70) and male/female ratio 19/9, received CT plus immunotherapy with subcutaneous IL-2 and INF. Doses were as follows: Cisplatinum 20 mg/m2 iv days 1–4, Vinblastine 1.6 mg/m2 iv days 1–4, Dacarbazine 800 mg/m2 iv day 1, Interferon α-2b 5M IU/m2 sc days 1–5, IL-2 9M IU sc days 1–5 and 8–12. Treatment was repeated every three weeks up to a maximum of six cycles. Response was assessed every two cycles and toxicity every cycle, according to WHO and NCI criteria respectively. Results: The overall response rate was 33% with 3 (11%) complete responses, lasting for 17, 14 and 24+ months respectively. There were 6 (22%) partial responses and 3 stable disease. 3 responders progressed in the central nervous system (CNS). For the whole population, median time to progression and survival were 3.5 and 9 months respectively. The most common G3–4 toxicity was neutropenia, reported in 25/28 (92%) pts. Only 2 pts (7%) experienced neutropenic fever. Less frequent was G3–4 thrombocytopenia, observed in 6/28 (21%) pts, with only 1 pt needing platelet support. G1–2 nausea and vomiting as well as fever following cytokine injections were reported in all pts. 1 toxic death occurred, due to neutropenic fever. Conclusions: This schedule with sc IL-2 had an acceptable level of toxicity and although the response rate was lower, TTP and OS were comparable to those reported with more intensive regimens. Several pts progressed in the CNS, suggesting that new combinations able to prevent this event are needed. No significant financial relationships to disclose." @default.
- W2527388725 created "2016-10-07" @default.
- W2527388725 creator A5008529443 @default.
- W2527388725 creator A5020136563 @default.
- W2527388725 creator A5020419436 @default.
- W2527388725 creator A5024846314 @default.
- W2527388725 creator A5054386184 @default.
- W2527388725 creator A5075663363 @default.
- W2527388725 creator A5080849411 @default.
- W2527388725 date "2004-07-15" @default.
- W2527388725 modified "2023-09-25" @default.
- W2527388725 title "Combined chemo-immunotherapy for metastatic melanoma. A monoinstitutional experience" @default.
- W2527388725 doi "https://doi.org/10.1200/jco.2004.22.90140.7569" @default.
- W2527388725 hasPublicationYear "2004" @default.
- W2527388725 type Work @default.
- W2527388725 sameAs 2527388725 @default.
- W2527388725 citedByCount "0" @default.
- W2527388725 crossrefType "journal-article" @default.
- W2527388725 hasAuthorship W2527388725A5008529443 @default.
- W2527388725 hasAuthorship W2527388725A5020136563 @default.
- W2527388725 hasAuthorship W2527388725A5020419436 @default.
- W2527388725 hasAuthorship W2527388725A5024846314 @default.
- W2527388725 hasAuthorship W2527388725A5054386184 @default.
- W2527388725 hasAuthorship W2527388725A5075663363 @default.
- W2527388725 hasAuthorship W2527388725A5080849411 @default.
- W2527388725 hasConcept C121608353 @default.
- W2527388725 hasConcept C126322002 @default.
- W2527388725 hasConcept C141071460 @default.
- W2527388725 hasConcept C2776694085 @default.
- W2527388725 hasConcept C2777063308 @default.
- W2527388725 hasConcept C2777132456 @default.
- W2527388725 hasConcept C2777658100 @default.
- W2527388725 hasConcept C2777701055 @default.
- W2527388725 hasConcept C2780964509 @default.
- W2527388725 hasConcept C2781228144 @default.
- W2527388725 hasConcept C2781413609 @default.
- W2527388725 hasConcept C2908647359 @default.
- W2527388725 hasConcept C29730261 @default.
- W2527388725 hasConcept C31760486 @default.
- W2527388725 hasConcept C502942594 @default.
- W2527388725 hasConcept C71924100 @default.
- W2527388725 hasConcept C90924648 @default.
- W2527388725 hasConcept C99454951 @default.
- W2527388725 hasConceptScore W2527388725C121608353 @default.
- W2527388725 hasConceptScore W2527388725C126322002 @default.
- W2527388725 hasConceptScore W2527388725C141071460 @default.
- W2527388725 hasConceptScore W2527388725C2776694085 @default.
- W2527388725 hasConceptScore W2527388725C2777063308 @default.
- W2527388725 hasConceptScore W2527388725C2777132456 @default.
- W2527388725 hasConceptScore W2527388725C2777658100 @default.
- W2527388725 hasConceptScore W2527388725C2777701055 @default.
- W2527388725 hasConceptScore W2527388725C2780964509 @default.
- W2527388725 hasConceptScore W2527388725C2781228144 @default.
- W2527388725 hasConceptScore W2527388725C2781413609 @default.
- W2527388725 hasConceptScore W2527388725C2908647359 @default.
- W2527388725 hasConceptScore W2527388725C29730261 @default.
- W2527388725 hasConceptScore W2527388725C31760486 @default.
- W2527388725 hasConceptScore W2527388725C502942594 @default.
- W2527388725 hasConceptScore W2527388725C71924100 @default.
- W2527388725 hasConceptScore W2527388725C90924648 @default.
- W2527388725 hasConceptScore W2527388725C99454951 @default.
- W2527388725 hasIssue "14_suppl" @default.
- W2527388725 hasLocation W25273887251 @default.
- W2527388725 hasOpenAccess W2527388725 @default.
- W2527388725 hasPrimaryLocation W25273887251 @default.
- W2527388725 hasRelatedWork W1993837524 @default.
- W2527388725 hasRelatedWork W2027567030 @default.
- W2527388725 hasRelatedWork W2058508302 @default.
- W2527388725 hasRelatedWork W2119233294 @default.
- W2527388725 hasRelatedWork W2121662958 @default.
- W2527388725 hasRelatedWork W2125837906 @default.
- W2527388725 hasRelatedWork W2356441863 @default.
- W2527388725 hasRelatedWork W2397644467 @default.
- W2527388725 hasRelatedWork W2412065260 @default.
- W2527388725 hasRelatedWork W40246373 @default.
- W2527388725 hasVolume "22" @default.
- W2527388725 isParatext "false" @default.
- W2527388725 isRetracted "false" @default.
- W2527388725 magId "2527388725" @default.
- W2527388725 workType "article" @default.